Sai Thankamony

- Highly innovative biomarker lead driving strategy and execution for APG777/zumilokibart development in Atopic Dermatitis. - Built and led a high performing team of clinical biomarker leads, assay scientists and operations leads to support clinical program and study goals. -Leadership in the development and oversight of global clinical biomarker strategies and execution across portfolio in I&I indications of Dermatology, Respiratory and GI. -Contribute to development of clinical protocols, ICF and other regulatory submissions related to biomarkers. -Stay ahead on new technologies for biomarker discovery, patient outcomes research and new target discovery. -Ensure excellence in clinical biomarker tools by using the right technological platforms and right assays, qualified/validated according to evolving biomarker context of use. -Drive long range strategic planning, budget planning, and cross-functional execution. -Manage and oversee external collaborations, communicate biomarker data and impact to stakeholders and, accountable for all aspects related to clinical biomarkers across portfolio. -Managed a team of 9 reports -Disease areas: Atopic Dermatitis, Asthma, COPD, EOE

-Clinical biomarker strategy and execution utilizing fluid, digital, and imaging tools for neuro and rare indications. -Focus on patient stratification, enrichment, PD and disease biomarkers. -Clinical study design and protocols. -Biomarker evidence generation. -New indications diligence, in neuro and rare, in collaboration with commercial partners. -Preclinical PK/PD study design and execution. - Disease areas: Alzheimer’s Disease, PSP, ALS

-Biomarker discovery to identify, evaluate, and characterize PD and efficacy biomarkers in FSHD. -Biomarker operations and strategic lead for Ph3 clinical program. -Disease areas: FSHD, COVID-19

- Group Lead managing a team of 4 supporting biomarker strategies across entire portfolio (Oncology, I/O, and Immunology (SLE, Psoriasis)) to accelerate drug discovery and development. - Execute on high level operational plans, processes, and strategies for stakeholder engagement spanning discovery and translational teams, refine soluble biomarker plan, develop clinical grade assays, prioritize for timely execution of assays for portfolio support. - Implementation and adoption of industry best practices for biomarker assays, SOP generation. - Supervision and mentoring a team of 4-direct reports.

- Clinical Biomarker Lead for multiple programs across discovery and development for neurodegenerative and rare diseases including SOD1 BIIB067/QALSODY in ALS and PLEGRIDY for MS (post-launch phase). - Led the development and execution of biomarker strategy in cross-functional team of Medical Directors, Clinical Pharmacologists, Clinical Development, Preclinical Scientists, Toxicologists, and Biostatistics. - Strategic, scientific, technical accountability for biomarker discovery, biomarker assay development, and deployment in support of clinical studies. - Excellent prioritization skills to achieve program and portfolio goals. - Management of external scientific and vendor collaborations. - Managed a team of 3 reports. Key Indications: ALS, MS, Tissue Injury and Fibrosis

-Development of biomarker assays and generation of critical data on PD and target engagement measures to support R2D transition of programs in immunology and CKD.

Colon cancer and mesenchymal stem cell research.

Translational research in Osteoarthritis.